Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

3 months ago CAR-T

Breakthrough Therapy Brings New Hope: Swiss Patient Thomas Begins CAR-T Treatment at Tongji Hospital, Wuhan

Professor Li Chunrui’s team at Tongji Hospital in Wuhan successfully conducted a case of chimeric antigen receptor T-cell (CAR-T) immunotherapy for a patient with relapsed and refractory multiple myeloma, offering new life to Swiss patient Thomas.

Thomas, a 54-year-old patient from Switzerland, has been battling multiple myeloma for nearly ten years. Initially diagnosed in 2016, he has endured severe bone pain and undergone multiple rounds of systemic chemotherapy and monoclonal antibody therapy. Although his condition was temporarily controlled, repeated relapses, with the most recent in 2022, made treatment increasingly challenging.

However, the global development of CAR-T therapy has reignited hope. The introduction of FUCASO (Eque-cel), the first fully human CAR-T product in mainland China, has brought new light to Thomas. This groundbreaking treatment not only boasts low immunogenicity but also offers prolonged efficacy, enabling patients to return to a high quality of life.

Thomas ultimately chose to receive the cutting-edge CAR-T therapy at Tongji Hospital, seeking a fundamental breakthrough in his treatment. The apheresis procedure was conducted by the hospital’s top hematology team, who possess international-level expertise and place special emphasis on patient-specific needs and treatment safety. The attending physician elaborated on the apheresis process in an interview, saying, “We precisely collected T-cells from Thomas’s body, then modified these cells in a controlled environment to specifically target multiple myeloma cancer cells. The use of FUCASO greatly enhanced the treatment’s specificity and success rate.”

Thomas expressed high recognition and appreciation for the hospital team’s professionalism and the transparency of the treatment process. Tongji Hospital leveraged its advanced technology and equipment to provide Thomas with a smooth and efficient apheresis experience, ensuring high-quality T-cell collection and paving the way for the subsequent treatment.

Thomas is now filled with confidence and anticipation, looking forward to the new life that CAR-T therapy promises. This new beginning marks a significant step in his treatment journey, injecting new hope into his path to recovery.

We will continue to follow up on the patient’s subsequent treatment and report on the progress.

CART MultipleMyeloma FUCASOJourney Equecel TongjiHospital CancerSurvivor BloodCancer Immunotherapy FullyHumanCART CancerTreatment

6 months ago CAR-T

China’s another cancer center launches an international medical department, offering comprehensive one-stop medical services to overseas patients

China’s another cancer center launches an international medical department, offering comprehensive one-stop medical services to overseas patients.

cancer center

The International Medical Department of Tongji Hospital,

affiliated with Tongji University in Shanghai, has recently been officially launched. The department focuses on providing international medical services and aims to offer overseas patients a one-stop, seamless medical experience with high-quality and convenient healthcare services.

The advantages

of the International Medical Department at Tongji Hospital go beyond providing one-stop, comprehensive medical services to overseas patients. It also means that overseas patients can receive a full range of medical services, from initial consultation to treatment and recovery, all in one place, without the need for frequent referrals or seeking treatment across multiple hospitals. The department is equipped with advanced facilities and equipment, including PET-CT scanners, linear accelerators (LA), high-end MRI and CT scanners, DSA machines, as well as integrated hybrid operating rooms, laparoscopic surgery systems, and 4K3D high-definition laparoscopes, providing patients with state-of-the-art diagnostic and treatment methods.

Furthermore, as another cancer center in China

it offers the most advanced CAR-T cell therapy globally to all overseas patients. Tongji Hospital, well-known for its cancer treatment expertise in China, has accumulated rich experience and professional knowledge in the field of

CAR-T cell therapy

, enabling them to provide personalized and customized medical solutions for patients. The International Medical Department primarily serves high-end commercial insurance clients, foreign patients, overseas Chinese, diplomats and their families, and international corporate employees. The services provided by the department include initial consultation assessments, disease diagnosis, treatment plan development, surgeries and interventional therapies, rehabilitation, and follow-up care.

The medical team

is the core strength of the department. The International Medical Department at Tongji Hospital has recruited a team of foreign physicians, clinical experts, and returning young doctors from Tongji Hospital, covering almost all clinical specialties. In addition, the department regularly invites internationally renowned experts to visit, such as Professor Kurt Fritzsch, a professor of psychosomatic medicine at the University of Freiburg in Germany, and Professor Claus Cursiefen, a professor of ophthalmology at the University of Cologne in Germany. Especially as a cancer center in China, Tongji Hospital also has a team with the highest number of CAR-T cancer treatment cases worldwide, ensuring the provision of top-quality medical services to patients.

If patients are interested in seeking treatment in China

and staying at the International Medical Department of Tongji Hospital in Shanghai, or if they want to inquire about China’s cancer centers and the highest level of CAR-T therapy worldwide, the team at “Advanced medicine in China” will provide all the relevant services. These services include, but are not limited to, expert evaluations, online consultations with specialists, insurance service consultations, multilingual accompanying services, multilingual medical consultations and translation services, disease diagnosis, customized treatment plans, surgeries, interventional therapies, CAR-T treatments, hospitalization services, emergency rescue, referral services, medical companions, services for accompanying family members, and post-recovery guidance, among other value-added services, fully meeting the needs of patients.

WhatsApp: +86137 1795 9070

Email: doctor.huang@globecancer.com

6 months ago Myeloma , CAR-T

Hope Reborn for Multiple Myeloma Patients – The Beginning of CAR-T Therapy

🎯Hope Reborn for Multiple Myeloma Patients – The Beginning of CAR-T Therapy🎯

⭐ Recently, Professor Li Ping’s team at Tongji Hospital in Shanghai successfully carried out Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) treatment for a relapsed and refractory multiple myeloma (R/RMM) patient. This therapy brings new hope for the treatment of R/RMM patients.🌟 The patient who underwent CAR-T treatment was diagnosed with multiple myeloma in Thailand in July 2021. With a high tumor burden and aggressive disease, despite receiving systemic chemotherapy, monoclonal antibodies, autologous hematopoietic stem cell transplantation (ASCT), and other treatments, the disease recurred multiple times. Within just 2 years of the disease course, the patient developed resistance to multi-line treatments, making it difficult to control the disease effectively.

🌠 As the number of relapses increases in R/RMM patients and the number of treatment lines expands, the response to treatment worsens, and the duration of remission becomes shorter. However, with the approval of the world’s first fully human CAR-T therapy drug, FUCASO (Eque-cel), in mainland China, new hope has undoubtedly been ignited for the treatment of multiple myeloma. Its breakthrough fully human CAR structure not only has low immunogenicity but also rapid dissociation and low exhaustion, allowing patients to return to a higher quality of life with just one treatment.

☄ After evaluation by Professor Li Ping’s team, the patient met the criteria for CAR-T cell therapy. After thorough communication between doctors and the patient and their family, the patient ultimately chose to undergo CAR-T therapy and completed peripheral blood mononuclear cell collection in November 2023.

✨ We will continue to monitor the patient’s treatment progress and provide follow-up reports.

#CARTTreatment #CARTTherapy #HopeReborn #FUCASOApproval #EquecelApproval #MultipleMyeloma #TongjiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART
Note: Imaging and data have been authorized by the hospital, patients, and patients’ families.

Menu

Tags Archives: Tongji Hospital

Breakthrough Therapy Brings New Hope: Swiss Patient Thomas Begins CAR-T Treatment at Tongji Hospital, Wuhan